Kura Oncology Correlations

KURA Stock  USD 6.67  0.20  3.09%   
The current 90-days correlation between Kura Oncology and Syndax Pharmaceuticals is 0.76 (i.e., Poor diversification). The correlation of Kura Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Kura Oncology Correlation With Market

Weak diversification

The correlation between Kura Oncology and DJI is 0.32 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and DJI in the same portfolio, assuming nothing else is changed.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.

Moving together with Kura Stock

  0.68FATE Fate Therapeutics Earnings Call This WeekPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations   
ANABCOGT
KALVCOGT
ANABKALV
MRSNSNDX
MRSNCGEM
CGEMSNDX
  
High negative correlations   
COGTSNDX
ANABSNDX
CGEMCOGT
MRSNCOGT
ANABMRSN

Risk-Adjusted Indicators

There is a big difference between Kura Stock performing well and Kura Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kura Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Kura Oncology Corporate Management

Kathleen FordChief OfficerProfile
Mollie MDExecutive DevelopmentProfile
Francis BurrowsSenior ResearchProfile
Roger BakaleClinical CMCProfile
Samir MSSenior LeadershipProfile
JD EsqChief SecretaryProfile
Marc MDAdvisorProfile